ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1601819
Efficacy Prediction of Neoadjuvant Cadonilimab Plus FLOT Therapy for Advanced Gastric Cancer: A Study Based on Body Composition Changes
Provisionally accepted
- 1Lanzhou University, Lanzhou, China
- 2Lanzhou University Second Hospital, Lanzhou, Gansu Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This study aimed to explore the predictive value of body composition changes in the efficacy of neoadjuvant cadonilimab combined with FLOT therapy for advanced gastric cancer and provide a reference for personalized treatment.A retrospective study was conducted on 33 patients with advanced gastric cancer who received neoadjuvant cadonilimab combined with FLOT therapy and subsequently underwent surgery.Body composition data were obtained using the InBody 720 body composition analysis device.Based on treatment response,patients were classified into the objective response group and the no-progression group.Quantitative data were presented as median and interquartile range.The Mann-Whitney U test was used for intergroup comparisons,analyzing the relationship between body composition changes before and after neoadjuvant therapy and treatment outcomes.The changes in LBM, SLM, SMM, VFA, LEFT ARM SLM, RIGHT ARM SLM, LEFT LEG SLM, RIGHT LEG SLM, TRUNK SLM and IMPEDANCE before and after neoadjuvant therapy showed significant differences (P < 0.05) between two groups,indicating statistical significance.LBM, SLM and SMM showed a decreasing trend in both groups and the reduction was greater in the no-progression group than in the objective response group;VFA expressed a significant reduction in the objective response group,but it tended to increase in the no-progression group;IMPEDANCE showed a significant increase in the objective response group,but the change was insignificant in the no-progression group.SLM in the trunk and limbs showed a decreasing trend in both groups and the reduction was greater in the no-progression group than in the objective response group.The changes in HEIGHT, WEIGHT, BFM, PBF, LEFT ARM MBF, RIGHT ARM MBF, LEFT LEG MBF, RIGHT LEG MBF, TRUNK MBF, WHR and WAIST showed no significant differences (P ≥ 0.05) between two groups, indicating they were not statistically significant.
Keywords: Neoadjuvant Therapy, Cadonilimab, Flot, Advanced gastric cancer, Body Composition, efficacy prediction
Received: 28 Mar 2025; Accepted: 25 Jul 2025.
Copyright: © 2025 Liu, Li, Wang, Guo, Guo, Shi and Mao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jie Mao, Lanzhou University Second Hospital, Lanzhou, 730030, Gansu Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.